Predict your next investment

Sensei company logo
INTERNET | Internet Software & Services / Retail & Inventory
sensei.tech

See what CB Insights has to offer

Competitors

2

Business Relationships

1

Service Providers

1

Sensei Competitors & Alternatives

2 Competitors

Sensei has 2 competitors. Sensei's competitors are Trigo and more.

Latest Funding

Companies

Investment Stage

Total Funding

Mosaic
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

Location

6/16/2021

Unattributed

$105M

000

Israel

10/3/2018

Black.ai

Seed VC

$0.87M

000

Australia

Latest Funding

6/16/2021

10/3/2018

Companies

Black.ai

Investment Stage

Unattributed

Seed VC

Total Funding

$105M

$0.87M

Mosaic

000

000

Location

Israel

Australia

Sensei Service Providers

1 Service Provider

Sensei has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Odeon Capital Group

Seed

Investment Bank

Financial Advisor

Service Provider

Odeon Capital Group

Associated Rounds

Seed

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Sensei Partners & Customers

1 Partners and customers

Sensei has 1 strategic partners and customers. Sensei recently partnered with AstraZeneca on May 5, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

5/7/2019

Partner

AstraZeneca

United Kingdom

Sensei Biotherapeutics Announces Clinical Trial Collaboration Agreement with AstraZeneca for Two Phase 2 Studies of SNS-301

Under the terms of the agreement , AstraZeneca and Sensei will collaborate to evaluate the combination of SNS-301 and IMFINZI ® in patients with locally advanced head and neck cancer in the neoadjuvant setting in conjunction with TPF chemotherapy prior to surgical resection and in ASPH + patients with various locally advanced unresectable or metastatic/recurrent solid tumors .

1

Date

5/7/2019

Type

Partner

Business Partner

AstraZeneca

Country

United Kingdom

News Snippet

Sensei Biotherapeutics Announces Clinical Trial Collaboration Agreement with AstraZeneca for Two Phase 2 Studies of SNS-301

Under the terms of the agreement , AstraZeneca and Sensei will collaborate to evaluate the combination of SNS-301 and IMFINZI ® in patients with locally advanced head and neck cancer in the neoadjuvant setting in conjunction with TPF chemotherapy prior to surgical resection and in ASPH + patients with various locally advanced unresectable or metastatic/recurrent solid tumors .

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.